Sung Ji Nam

Destiny Buch

Joanne Lee

Mark Massaro

Michael Okunewitch

Michael Okunowicz

Vidyun Bais

Vivian Cervantes

Yi Chen

- Bionano projects **2025 revenue guidance of $26 million to $30 million**, with a strategic pivot towards driving utilization of high-margin OGM consumables among existing customers.  **[0001411690_2185980_14]** **[0001411690_2185980_15]** 
- The company has addressed key adoption hurdles, including establishing **CPT codes** for hematologic malignancies (2024) and constitutional genetic disorders (2025), and is the **sole provider of optical genome mapping (OGM)** technology.  **[0001411690_2185980_12]** **[0001411690_2185980_14]** 
- Bionano reported **Q2 2025 software revenues of approximately $1.3 million to $1.4 million** and has substantially reduced non-GAAP operating expenses from **$35 million per quarter in 2023 to $8.5 million to $9 million per quarter**.  **[0001411690_2185980_7]** **[0001411690_2185980_15]** 
- Despite a recent financing extending its runway, Bionano anticipates needing further capital to achieve cash flow breakeven.  **[0001411690_2185980_15]**

Bionano Outlines 2025 Revenue Guidance and Strategic Shift

- Bionano Genomics, Inc. announced the **pricing of a public offering** on September 16, 2025, for an aggregate of **5,000,000 shares of common stock** (or common stock equivalents) and accompanying Series E and Series F warrants.  **[1411690_0001140361-25-035286_ny20052513x7_ex99-1.htm:0]** 
- The combined public offering price was **$2.00 per share** (or common stock equivalent) and accompanying Series Warrants, with an exercise price of **$2.00 per share** for the warrants.  **[1411690_0001140361-25-035286_ny20052513x7_ex99-1.htm:0]** 
- The offering is expected to generate approximately **$10 million in gross proceeds** before deductions, with potential additional gross proceeds of approximately **$20 million** if the Series Warrants are fully exercised.  **[1411690_0001140361-25-035286_ny20052513x7_ex99-1.htm:0]** 
- The net proceeds, approximately **$9.0 million**, will be used for **working capital and general corporate purposes**.  **[1411690_0001140361-25-035286_ny20052513x7_ex99-1.htm:0]** **[1411690_0001140361-25-035286_ny20052513x7_8k.htm:2]** 
- The offering closed on **September 17, 2025**.  **[1411690_0001140361-25-035286_ny20052513x7_ex99-2.htm:0]** **[1411690_0001140361-25-035286_ny20052513x7_8k.htm:2]**

Bionano Genomics Prices $10 Million Public Offering

Bionano Genomics (BNGO)